{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T21:09:38Z","timestamp":1782162578217,"version":"3.54.5"},"reference-count":196,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073479"],"award-info":[{"award-number":["82073479"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bbcan.2025.189406","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T19:30:48Z","timestamp":1754422248000},"page":"189406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical aspect of combined immunotherapy and radiotherapy effect on tumor immune microenvironment in hepatobiliary and pancreatic cancers"],"prefix":"10.1016","volume":"1880","author":[{"given":"Jun-Jie","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Lan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Xing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Suo","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbcan.2025.189406_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189406_bb0010","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","article-title":"Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review","volume":"10","author":"Cappuyns","year":"2024","journal-title":"JAMA Oncol."},{"issue":"24","key":"10.1016\/j.bbcan.2025.189406_bb0015","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1200\/JCO.21.02576","article-title":"Precision medicine in biliary tract Cancer","volume":"40","author":"Scott","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","article-title":"Therapeutic developments in pancreatic cancer","volume":"21","author":"Hu","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jhep.2020.04.019","article-title":"Stereotactic body radiotherapy for hepatocellular carcinoma - still searching for a role","volume":"73","author":"Meyer","year":"2020","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189406_bb0030","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3390\/curroncol30020190","article-title":"Stereotactic body radiotherapy for hepatocellular carcinoma: a brief overview","volume":"30","author":"Matsuo","year":"2023","journal-title":"Curr. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189406_bb0035","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/cac2.12576","article-title":"Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors","volume":"44","author":"Wu","year":"2024","journal-title":"Cancer Commun. (Lond.)"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189406_bb0040","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","volume":"20","author":"Galluzzi","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189406_bb0045","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ijrobp.2023.12.046","article-title":"The next chapter in immunotherapy and radiation combination therapy: Cancer-specific perspectives","volume":"118","author":"Wisdom","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bbcan.2025.189406_bb0050","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-immunol-051116-052415","article-title":"Immune responses in the liver","volume":"36","author":"Kubes","year":"2018","journal-title":"Annu. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189406_bb0055","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nri2858","article-title":"Antigen-presenting cell function in the tolerogenic liver environment","volume":"10","author":"Thomson","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189406_bb0060","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/hep.1840080207","article-title":"Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis","volume":"8","author":"Lumsden","year":"1988","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189406_bb0065","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrgastro.2015.94","article-title":"Inflammasome activation and function in liver disease","volume":"12","author":"Szabo","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0070","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hep.24341","article-title":"Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells","volume":"54","author":"Csak","year":"2011","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189406_bb0075","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41575-020-0284-x","article-title":"Polyploidy in liver development, homeostasis and disease","volume":"17","author":"Donne","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189406_bb0080","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","article-title":"Precision treatment in advanced hepatocellular carcinoma","volume":"42","author":"Yang","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0085","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","article-title":"Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification","volume":"72","author":"Montironi","year":"2023","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189406_bb0090","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189406_bb0095","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/hep.31092","article-title":"Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma","volume":"72","author":"Job","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189406_bb0100","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189406_bb0105","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1172\/JCI95351","article-title":"\u0392-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas","volume":"128","author":"Nsengimana","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/annonc\/mdy470","article-title":"Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy","volume":"30","author":"Chen","year":"2019","journal-title":"Ann. Oncol."},{"issue":"7938","key":"10.1016\/j.bbcan.2025.189406_bb0115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-022-05400-x","article-title":"Liver tumour immune microenvironment subtypes and neutrophil heterogeneity","volume":"612","author":"Xue","year":"2022","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189406_bb0120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189406_bb0125","unstructured":"Y. Liu, Z. Xun, K. Ma, S. Liang, X. Li, S. Zhou, L. Sun, Y. Liu, Y. Du, X. Guo, T. Cui, H. Zhou, J. Wang, D. Yin, R. Song, S. Zhang, W. Cai, F. Meng, H. Guo, B. Zhang, D. Yang, R. Bao, Q. Hu, J. Wang, Y. Ye, L. Liu, Identification of a Tumour Immune Barrier in the HCC Microenvironment That Determines the Efficacy of Immunotherapy, (1600\u20130641 (Electronic))."},{"issue":"20","key":"10.1016\/j.bbcan.2025.189406_bb0130","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189406_bb0135","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"issue":"10415","key":"10.1016\/j.bbcan.2025.189406_bb0140","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189406_bb0145","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","article-title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","volume":"7","author":"Marron","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189406_bb0150","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","article-title":"Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity","volume":"2","author":"Ho","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.bbcan.2025.189406_bb0155","unstructured":"T.A.-O. Greten, R.A.-O. Schwabe, N.A.-O. Bardeesy, L. Ma, L. Goyal, R.A.-O. Kelley, X.W. Wang, Immunology and Immunotherapy of Cholangiocarcinoma, (1759\u20135053 (Electronic))."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189406_bb0165","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ccell.2021.03.012","article-title":"Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations","volume":"39","author":"Affo","year":"2021","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189406_bb0170","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","article-title":"Immunology and immunotherapy of cholangiocarcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189406_bb0175","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.neo.2019.10.005","article-title":"Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment","volume":"21","author":"Lin","year":"2019","journal-title":"Neoplasia"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189406_bb0180","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146987","article-title":"Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts","volume":"131","author":"Bhattacharjee","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"15","key":"10.1016\/j.bbcan.2025.189406_bb0185","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1111\/febs.14777","article-title":"Hyaluronan: molecular size-dependent signaling and biological functions in inflammation and cancer","volume":"286","author":"Tavianatou","year":"2019","journal-title":"FEBS J."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189406_bb0190","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189406_bb0195","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","article-title":"Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study","volume":"4","author":"Ueno","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189406_bb0200","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"10391","key":"10.1016\/j.bbcan.2025.189406_bb0205","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189406_bb0210","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0215","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/gutjnl-2023-330029","article-title":"British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma","volume":"73","author":"Rushbrook","year":"2023","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189406_bb0220","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.coi.2013.01.006","article-title":"Inflammatory networks and immune surveillance of pancreatic carcinoma","volume":"25","author":"Vonderheide","year":"2013","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0225","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.celrep.2017.03.037","article-title":"Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis","volume":"19","author":"Tsujikawa","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2025.189406_bb0230","unstructured":"E. Karamitopoulou, Tumour Microenvironment of Pancreatic Cancer: Immune Landscape is Dictated by Molecular and Histopathological Features, (1532\u20131827 (Electronic))."},{"key":"10.1016\/j.bbcan.2025.189406_bb0235","unstructured":"J. Yang, Q. Zhang, J. Wang, Y. Lou, Z. Hong, S. Wei, K. Sun, J. Wang, Y. Chen, J. Sheng, W. Su, X. Bai, T. Liang, Dynamic Profiling of Immune Microenvironment During Pancreatic Cancer Development Suggests Early Intervention and Combination Strategy of Immunotherapy, (2352\u20133964 (Electronic))."},{"key":"10.1016\/j.bbcan.2025.189406_bb0240","unstructured":"C.W.F. van Eijck, J. Ju, F.R. van 't Land, M. Verheij, Y. Li, A. Stubbs, M. Doukas, K. Lila, L.R. Heij, G. Wiltberger, L. Alonso, N. Malats, B. Groot Koerkamp, E.E. Vietsch, C.H.J. van Eijck, The Tumor Immune Microenvironment in Resected Treatment-naive Pancreatic Cancer Patients With Long-term Survival, (1424\u20133911 (Electronic))."},{"issue":"26","key":"10.1016\/j.bbcan.2025.189406_bb0245","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189406_bb0250","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without Tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"O\u2019Reilly","year":"2019","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189406_bb0255","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J. Immunother."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189406_bb0260","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/14737159.2023.2281482","article-title":"The tumor immune microenvironment in pancreatic cancer and its potential in the identification of immunotherapy biomarkers","volume":"23","author":"Tsunedomi","year":"2023","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189406_bb0265","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/gut.2010.226092","article-title":"Stromal biology and therapy in pancreatic cancer","volume":"60","author":"Neesse","year":"2011","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189406_bb0270","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189406_bb0275","unstructured":"Y.H. Zhu, J.H. Zheng, Q.Y. Jia, Z.H. Duan, H.F. Yao, J. Yang, Y.W. Sun, S.H. Jiang, D.J. Liu, Y.M. Huo, Immunosuppression, Immune Escape, and Immunotherapy in Pancreatic Cancer: Focused on the Tumor Microenvironment, (2211\u20133436 (Electronic))."},{"key":"10.1016\/j.bbcan.2025.189406_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.743907","article-title":"The cellular origins of Cancer-associated fibroblasts and their opposing contributions to pancreatic Cancer growth","volume":"9","author":"Manoukian","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189406_bb0285","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1084\/jem.20162024","article-title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"\u00d6hlund","year":"2017","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189406_bb0290","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting Cancer-associated fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov."},{"issue":"50","key":"10.1016\/j.bbcan.2025.189406_bb0295","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189406_bb0300","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"\u00d6zdemir","year":"2014","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189406_bb0305","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","article-title":"Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","volume":"25","author":"Rhim","year":"2014","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.bbcan.2025.189406_bb0310","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1016\/j.cell.2021.09.022","article-title":"Spatially confined sub-tumor microenvironments in pancreatic cancer","volume":"184","author":"Gr\u00fcnwald","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2025.189406_bb0315","unstructured":"X. Xiang, J. Wang, D. Lu, X. Xu, Targeting Tumor-associated Macrophages to Synergize Tumor Immunotherapy, (2059\u20133635 (Electronic))."},{"key":"10.1016\/j.bbcan.2025.189406_bb0320","unstructured":"L. Fabris, K. Sato, G. Alpini, M. Strazzabosco, The Tumor Microenvironment in Cholangiocarcinoma Progression, (1527\u20133350 (Electronic))."},{"key":"10.1016\/j.bbcan.2025.189406_bb0325","unstructured":"D. Pan, X. Li, X. Qiao, Q. Wang, Immunosuppressive Tumor Microenvironment in Pancreatic Cancer: Mechanisms and Therapeutic Targets, (1664\u20133224 (Electronic))."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189406_bb0330","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41590-019-0561-4","article-title":"Immunological impact of cell death signaling driven by radiation on the tumor microenvironment","volume":"21","author":"Rodriguez-Ruiz","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbcan.2025.189406_bb0335","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2019.02.048","article-title":"Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and\/or chemotherapy","volume":"452","author":"Yu","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2025.189406_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-immunol-100311-102839","article-title":"Decisions about dendritic cells: past, present, and future","volume":"30","author":"Steinman","year":"2012","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0345","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189406_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106761","article-title":"Damage-associated molecular patterns in tumor radiotherapy","volume":"86","author":"Ashrafizadeh","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189406_bb0355","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.molcel.2014.03.040","article-title":"The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling","volume":"54","author":"Cai","year":"2014","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189406_bb0360","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ijrobp.2021.12.162","article-title":"Radiation therapy promotes hepatocellular carcinoma immune cloaking via PD-L1 upregulation induced by cGAS-STING activation","volume":"112","author":"Du","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0365","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/s41467-017-01566-5","article-title":"Host STING-dependent MDSC mobilization drives extrinsic radiation resistance","volume":"8","author":"Liang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189406_bb0370","doi-asserted-by":"crossref","first-page":"1247268","DOI":"10.3389\/fimmu.2023.1247268","article-title":"Mechanisms and applications of radiation-induced oxidative stress in regulating cancer immunotherapy","volume":"14","author":"Zheng","year":"2023","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189406_bb0375","doi-asserted-by":"crossref","DOI":"10.1172\/JCI155224","article-title":"SENP7 senses oxidative stress to sustain metabolic fitness and antitumor functions of CD8+ T cells","volume":"132","author":"Wu","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189406_bb0380","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189406_bb0385","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.4049\/jimmunol.176.5.2765","article-title":"Oxidative stress promotes polarization of human T cell differentiation toward a T helper 2 phenotype","volume":"176","author":"King","year":"2006","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189406_bb0390","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.144394","article-title":"PDLIM2 repression by ROS in alveolar macrophages promotes lung tumorigenesis","volume":"6","author":"Li","year":"2021","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0395","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7054","key":"10.1016\/j.bbcan.2025.189406_bb0400","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nature03884","article-title":"The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor","volume":"436","author":"Gasser","year":"2005","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.bbcan.2025.189406_bb0405","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/blood-2008-08-173914","article-title":"ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype","volume":"113","author":"Soriani","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0410","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0415","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13046-019-1161-8","article-title":"Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK\/STAT3\/PD-L1 pathway","volume":"38","author":"Shen","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189406_bb0420","doi-asserted-by":"crossref","first-page":"eabh4050","DOI":"10.1126\/sciadv.abh4050","article-title":"Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8","volume":"8","author":"Walle","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2025.189406_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155709","article-title":"TGF-beta signaling in cancer radiotherapy","volume":"148","author":"Wang","year":"2021","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0430","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","article-title":"External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline","volume":"12","author":"Apisarnthanarax","year":"2022","journal-title":"Pract. Radiat. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189406_bb0435","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1159\/000368020","article-title":"2014 KLCSG-NCC Korea practice guidelines for the management of hepatocellular carcinoma: HCC diagnostic algorithm","volume":"32","author":"Lee","year":"2014","journal-title":"Dig. Dis."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189406_bb0440","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijrobp.2023.08.015","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma: Meta-analysis and international stereotactic radiosurgery society practice guidelines","volume":"118","author":"Bae","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0445","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-019-1100-5","article-title":"MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatment","volume":"18","author":"Bian","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189406_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110424","article-title":"Mechanism of immune activation mediated by genomic instability and its implication in radiotherapy combined with immune checkpoint inhibitors","volume":"199","author":"Wang","year":"2024","journal-title":"Radiother. Oncol."},{"issue":"16","key":"10.1016\/j.bbcan.2025.189406_bb0455","article-title":"RECQL4 inhibits radiation-induced tumor immune awakening via suppressing the cGAS-STING pathway in hepatocellular carcinoma","volume":"11","author":"Hong","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.bbcan.2025.189406_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216507","article-title":"Olaparib enhances radiation-induced systemic anti-tumor effects via activating STING-chemokine signaling in hepatocellular carcinoma","volume":"582","author":"Chen","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2025.189406_bb0465","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","author":"D'Andrea","year":"2018","journal-title":"DNA Repair (Amst)"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189406_bb0470","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","article-title":"The gut-liver axis and the intersection with the microbiome","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0475","doi-asserted-by":"crossref","first-page":"2119055","DOI":"10.1080\/19490976.2022.2119055","article-title":"Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma via STING signaling","volume":"14","author":"Li","year":"2022","journal-title":"Gut Microbes"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189406_bb0480","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/s41423-020-0395-x","article-title":"DNA sensing and associated type 1 interferon signaling contributes to progression of radiation-induced liver injury","volume":"18","author":"Du","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0485","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"J. Yu, M.D. Green, S. Li, Y. Sun, S.N. Journey, J.E. Choi, S.M. Rizvi, A. Qin, J.J. Waninger, X. Lang, Z. Chopra, I. El Naqa, J. Zhou, Y. Bian, L. Jiang, A. Tezel, J. Skvarce, R.K. Achar, M. Sitto, B.S. Rosen, F. Su, S.P. Narayanan, X. Cao, S. Wei, W. Szeliga, L. Vatan, C. Mayo, M.A. Morgan, C.A. Schonewolf, K. Cuneo, I. Kryczek, V.T. Ma, C.D. Lao, T.S. Lawrence, N. Ramnath, F. Wen, A.M. Chinnaiyan, M. Cieslik, A. Alva, W. Zou","year":"2021","journal-title":"Nat. Med."},{"issue":"14","key":"10.1016\/j.bbcan.2025.189406_bb0490","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.bbcan.2025.189406_bb0495","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis","volume":"30","author":"Horgan","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189406_bb0500","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.semradonc.2018.06.003","article-title":"Radiotherapy for biliary tract cancers","volume":"28","author":"Keane","year":"2018","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/j.bbcan.2025.189406_bb0505","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.radonc.2018.11.015","article-title":"Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma","volume":"132","author":"Brunner","year":"2019","journal-title":"Radiother. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.bbcan.2025.189406_bb0510","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/JCO.2024.42.16_suppl.4006","article-title":"Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC) (ABC-07): results from a randomized phase II trial","volume":"42","author":"Hawkins","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.bbcan.2025.189406_bb0515","doi-asserted-by":"crossref","DOI":"10.3390\/cells11152309","article-title":"Selective internal radiotherapy changes the immune profiles of extracellular vesicles and their immune origin in patients with inoperable cholangiocarcinoma","volume":"11","author":"Haag","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0520","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/ajco.13809","article-title":"Prognostic markers including immune and inflammatory factors predict outcomes in patients receiving postoperative radiation therapy for cholangiocarcinoma","volume":"19","author":"Mukai","year":"2023","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189406_bb0525","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/15384047.2020.1834792","article-title":"Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases","volume":"22","author":"Zhao","year":"2021","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bbcan.2025.189406_bb0530","doi-asserted-by":"crossref","first-page":"1239168","DOI":"10.3389\/fimmu.2023.1239168","article-title":"PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review","volume":"14","author":"Liao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189406_bb0535","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fmed.2020.00368","article-title":"Anti-PD-1 immunotherapy and radiotherapy for stage IV intrahepatic cholangiocarcinoma: a case report","volume":"7","author":"Liu","year":"2020","journal-title":"Front. Med. (Lausanne)"},{"issue":"29","key":"10.1016\/j.bbcan.2025.189406_bb0540","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1200\/JCO.2010.30.3446","article-title":"Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012\/FFCD-9203\/GERCOR phase II study","volume":"28","author":"Van Laethem","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0545","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1186\/s12885-022-09974-7","article-title":"Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial","volume":"22","author":"Ma","year":"2022","journal-title":"BMC Cancer"},{"issue":"13","key":"10.1016\/j.bbcan.2025.189406_bb0550","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1245\/s10434-021-10276-8","article-title":"Added value of radiotherapy following neoadjuvant FOLFIRINOX for Resectable and borderline Resectable pancreatic Cancer: a systematic review and Meta-analysis","volume":"28","author":"Janssen","year":"2021","journal-title":"Ann. Surg. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.bbcan.2025.189406_bb0555","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/JCO.2022.40.16_suppl.4008","article-title":"Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial","volume":"40","author":"Fietkau","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189406_bb0560","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41588-022-01134-8","article-title":"Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment","volume":"54","author":"Hwang","year":"2022","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189406_bb0565","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ijrobp.2017.04.014","article-title":"Stimulating innate immunity to enhance radiation therapy-induced tumor control","volume":"99","author":"Baird","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189406_bb0570","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004784","article-title":"Toll-like receptor 7\/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer","volume":"10","author":"Ye","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189406_bb0575","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ccell.2023.04.001","article-title":"Simultaneous targeting of PD-1 and IL-2R\u03b2\u03b3 with radiation therapy inhibits pancreatic cancer growth and metastasis","volume":"41","author":"Piper","year":"2023","journal-title":"Cancer Cell"},{"issue":"7930","key":"10.1016\/j.bbcan.2025.189406_bb0580","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","article-title":"PD-1-cis IL-2R agonism yields better effectors from stem-like CD8(+) T cells","volume":"610","author":"Codarri Deak","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189406_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113114","article-title":"Low-dose X-ray irradiation combined with FAK inhibitors improves the immune microenvironment and confers sensitivity to radiotherapy in pancreatic cancer","volume":"151","author":"Chen","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189406_bb0590","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.immuni.2015.03.009","article-title":"Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response","volume":"42","author":"Surace","year":"2015","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189406_bb0595","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/2326-6066.CIR-21-0435","article-title":"C3aR signaling inhibits NK-cell infiltration into the tumor microenvironment in mouse models","volume":"10","author":"Nandagopal","year":"2022","journal-title":"Cancer Immunol. Res."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189406_bb0600","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1158\/2767-9764.CRC-22-0069","article-title":"The combination of radiotherapy and complement C3a inhibition potentiates natural killer cell functions against pancreatic cancer","volume":"2","author":"Sodji","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.bbcan.2025.189406_bb0605","unstructured":"Y.J. Choi, M.J. Kim, Y.J. Lee, M. Choi, W.S. Shim, M. Park, Y.C. Kim, K.W. Kang, Prevention of Radiotherapy-induced Pro-tumorigenic Microenvironment by SFK Inhibitors, (1838\u20137640 (Electronic))."},{"key":"10.1016\/j.bbcan.2025.189406_bb0610","doi-asserted-by":"crossref","unstructured":"M.A.-O. Jarosz-Biej, R. Smolarczyk, T. Cicho\u0144, N. Ku\u0142ach, Tumor Microenvironment as A \"Game Changer\" in Cancer Radiotherapy. LID - https:\/\/doi.org\/10.3390\/ijms20133212 [doi] LID - 3212, (1422\u20132067 (Electronic)).","DOI":"10.3390\/ijms20133212"},{"key":"10.1016\/j.bbcan.2025.189406_bb0615","unstructured":"E. Nolan, V.L. Bridgeman, L.A.-O. Ombrato, A.A.-O. Karoutas, N. Rabas, C.A.N. Sewnath, M. Vasquez, F.A.-O. Rodrigues, S.A.-O. Horswell, P. Faull, R. Carter, I.A.-O. Malanchi, Radiation Exposure Elicits a Neutrophil-driven Response in Healthy Lung Tissue That Enhances Metastatic Colonization, (2662\u20131347 (Electronic))."},{"key":"10.1016\/j.bbcan.2025.189406_bb0620","unstructured":"A.E. Marciscano, N. Anandasabapathy, The Role of Dendritic Cells in Cancer and Anti-tumor Immunity, (1096\u20133618 (Electronic))."},{"issue":"10295","key":"10.1016\/j.bbcan.2025.189406_bb0625","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(21)00233-6","article-title":"Contemporary radiotherapy: present and future","volume":"398","author":"Chandra","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189406_bb0630","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cac2.12178","article-title":"Advancing to the era of cancer immunotherapy","volume":"41","author":"Wang","year":"2021","journal-title":"Cancer Commun. (Lond.)"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189406_bb0635","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"24","key":"10.1016\/j.bbcan.2025.189406_bb0640","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.3748\/wjg.v29.i24.3871","article-title":"Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: a phase II clinical trial","volume":"29","author":"Chen","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbcan.2025.189406_bb0645","unstructured":"E. Yao, J.A.-O. Chen, X. Zhao, Y. Zheng, X. Wu, F. Han, H. Huang, P. Liang, J. Liu, F. Wu, L.A.-O. Lin, Efficacy of Stereotactic Body Radiotherapy for Recurrent or Residual Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization, (2314\u20136141 (Electronic))."},{"key":"10.1016\/j.bbcan.2025.189406_bb0650","unstructured":"S. Gerum, C. Heinz, C. Belka, F. Walter, P. Paprottka, E.N. De Toni, F. Roeder, Stereotactic Body Radiation Therapy (SBRT) in Patients With Hepatocellular Carcinoma and Oligometastatic Liver Disease, (1748-717X (Electronic))."},{"key":"10.1016\/j.bbcan.2025.189406_bb0655","unstructured":"T.S. Su, P. Liang, H.Z. Lu, J. Liang, Y.C. Gao, Y. Zhou, Y. Huang, M.Y. Tang, J.N. Liang, Stereotactic Body Radiation Therapy for Small Primary or Recurrent Hepatocellular Carcinoma in 132 Chinese Patients, (1096\u20139098 (Electronic))."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189406_bb0660","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/CM9.0000000000003124","article-title":"Radiotherapy enhances efficacy of PD-1 inhibitors in advanced hepatocellular carcinoma: a propensity-matched real-world study","volume":"137","author":"Hsu","year":"2024","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189406_bb0665","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","article-title":"Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial","volume":"8","author":"Chiang","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbcan.2025.189406_bb0670","unstructured":"Y.J. Xiang, K. Wang, Y.T. Zheng, S. Feng, H.M. Yu, X.W. Li, X. Cheng, Y.Q. Cheng, J.K. Feng, L.P. Zhou, Y. Meng, J. Zhai, Y.F. Shan, S.Q. Cheng, Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory, (2234-943X (Print))."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189406_bb0675","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s12072-022-10396-7","article-title":"Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial","volume":"16","author":"Li","year":"2022","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.bbcan.2025.189406_bb0680","unstructured":"A. Juloori, R.R. Katipally, J.M. Lemons, A.K. Singh, R. Iyer, J.R. Robbins, B. George, W.A. Hall, S.P. Pitroda, F. Arif, J. Fung, A. Pillai, C.Y. Liao, M. Sharma, S.L. Liauw, Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced\/Unresectable Hepatocellular Carcinoma, (1879-355X (Electronic))."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189406_bb0685","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","article-title":"Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single Centre, phase 2 trial","volume":"6","author":"Tai","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbcan.2025.189406_bb0690","doi-asserted-by":"crossref","unstructured":"M.A.-O. de la Torre-Al\u00e1ez, A. Matilla, M. Varela, M. I\u00f1arrairaegui, M. Reig, J.L. Lled\u00f3, J.I. Arenas, S. Lorente, M. Testillano, L. M\u00e1rquez, L. Da Fonseca, J. Argem\u00ed, C. G\u00f3mez-Martin, M.A.-O. Rodriguez-Fraile, J.I. Bilbao, B. Sangro, Nivolumab After Selective Internal Radiation Therapy for the Treatment of Hepatocellular Carcinoma: A Phase 2, Single-arm Study. LID - https:\/\/doi.org\/10.1136\/jitc-2022-005457 ([doi] LID - e005457, (2051\u20131426 (Electronic))).","DOI":"10.1136\/jitc-2022-005457"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189406_bb0695","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.bbcan.2025.189406_bb0700","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: selective internal radiation therapy versus Sorafenib in Asia-Pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189406_bb0705","unstructured":"F.T. Kolligs, J.I. Bilbao, T. Jakobs, M. I\u00f1arrairaegui, J.M. Nagel, M. Rodriguez, A. Haug, D. D'Avola, M. op den Winkel, A. Martinez-Cuesta, C. Trumm, A. Benito, K. Tatsch, C.J. Zech, R.T. Hoffmann, B. Sangro, Pilot Randomized Trial of Selective Internal Radiation Therapy vs. Chemoembolization in Unresectable Hepatocellular Carcinoma, (1478\u20133231 (Electronic))."},{"key":"10.1016\/j.bbcan.2025.189406_bb0710","unstructured":"M.B. Pitton, C. Kloeckner, G.M. Ruckes, W. Wirth, M.A. Eichhorn, A. W\u00f6rns, M. Weinmann, P.R. Schreckenberger, G. Galle, C. Otto, C. Dueber, Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma, (1432-086X (Electronic))."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189406_bb0715","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ijrobp.2022.03.019","article-title":"The combination of radiation therapy and immunotherapy is effective and well-tolerated for Unresectable biliary tract Cancer","volume":"113","author":"Chen","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189406_bb0720","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A phase 2 multi-institutional study of Nivolumab for patients with advanced refractory biliary tract Cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0725","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0360-3016(90)90268-O","article-title":"The role of radiotherapy in the treatment of bile duct carcinoma","volume":"18","author":"Veeze-Kuijpers","year":"1990","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189406_bb0730","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0360-3016(03)00770-3","article-title":"Intraluminal low-dose-rate 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma","volume":"57","author":"Takamura","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bbcan.2025.189406_bb0735","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2024.04.011","article-title":"Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: results from the phase 2 multicohort LEAP-005 study","volume":"186","author":"Gonz\u00e1lez-Mart\u00edn","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189406_bb0740","doi-asserted-by":"crossref","first-page":"414","DOI":"10.21037\/hbsn-20-338","article-title":"Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma","volume":"9","author":"Lin","year":"2020","journal-title":"Hepatob. Surg. Nutr."},{"key":"10.1016\/j.bbcan.2025.189406_bb0745","doi-asserted-by":"crossref","first-page":"1084843","DOI":"10.3389\/fimmu.2023.1084843","article-title":"Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189406_bb0750","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00262-023-03399-2","article-title":"Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study","volume":"72","author":"Wang","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"13","key":"10.1016\/j.bbcan.2025.189406_bb0755","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133312","article-title":"Immunotherapy in biliary tract cancers: current standard-of-care and emerging strategies","volume":"15","author":"Lo","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189406_bb0760","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.3390\/curroncol28050293","article-title":"Ampullary carcinoma: an overview of a rare entity and discussion of current and future therapeutic challenges","volume":"28","author":"Rizzo","year":"2021","journal-title":"Curr Oncol"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189406_bb0765","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-19-3624","article-title":"Immune checkpoint blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma","volume":"26","author":"Xie","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"27","key":"10.1016\/j.bbcan.2025.189406_bb0770","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1200\/JCO.21.02511","article-title":"Randomized phase II study of Nivolumab with or without Ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic Cancer (CheckPAC)","volume":"40","author":"Chen","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189406_bb0775","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","article-title":"Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nat. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189406_bb0780","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(22)00066-3","article-title":"Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Zhu","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0785","first-page":"53","article-title":"Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine","volume":"9","author":"Huang","year":"2022","journal-title":"Mil. Med. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0790","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.2001.19.1.145","article-title":"Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation","volume":"19","author":"Jaffee","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189406_bb0795","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/SLA.0b013e3181fd271c","article-title":"A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma.A Phase II trial of safety, efficacy, and immune activation","volume":"253","author":"Lutz","year":"2011","journal-title":"Ann. Surg."},{"key":"10.1016\/j.bbcan.2025.189406_bb0800","doi-asserted-by":"crossref","unstructured":"J.M. Hardacre, M. Mulcahy, W. Small, M. Talamonti, J. Obel, S. Krishnamurthi, C.S. Rocha-Lima, H. Safran, H.J. Lenz, E.G. Chiorean, Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study, J. Gastrointest. Surg. 17(1) (2013) 94\u2013100; discussion p. 100\u20131.","DOI":"10.1007\/s11605-012-2064-6"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0805","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/SLA.0000000000004669","article-title":"A phase 3 randomized clinical trial of chemotherapy with or without Algenpantucel-L (HyperAcute-pancreas) immunotherapy in subjects with borderline Resectable or locally advanced Unresectable pancreatic Cancer","volume":"275","author":"Hewitt","year":"2022","journal-title":"Ann. Surg."},{"key":"10.1016\/j.bbcan.2025.189406_bb0810","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40425-016-0149-6","article-title":"A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"4","author":"Crocenzi","year":"2016","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189406_bb0815","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.3390\/curroncol29100541","article-title":"The role of immunotherapy in pancreatic Cancer","volume":"29","author":"Mukherji","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bbcan.2025.189406_bb0820","series-title":"Interferon-based Adjuvant Chemoradiation Therapy Improves Survival After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma","author":"Nukui","year":"2025"},{"key":"10.1016\/j.bbcan.2025.189406_bb0825","series-title":"Interferon-based Adjuvant Chemoradiation Therapy After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma","author":"Picozzi","year":"2025"},{"key":"10.1016\/j.bbcan.2025.189406_bb0830","series-title":"Interferon-based Adjuvant Chemoradiation for Resected Pancreatic Head Cancer: Long-term Follow-up of the Virginia Mason Protocol","author":"Rocha","year":"2025"},{"issue":"33","key":"10.1016\/j.bbcan.2025.189406_bb0835","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1200\/JCO.2011.38.2960","article-title":"Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma","volume":"30","author":"Schmidt","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189406_bb0840","series-title":"Inflammatory Microenvironment Remodelling by Tumour Cells After Radiotherapy","first-page":"1474","author":"McLaughlin","year":"2025"},{"key":"10.1016\/j.bbcan.2025.189406_bb0845","series-title":"Immune Microenvironment and Immunotherapy in Hepatocellular Carcinoma: Mechanisms and Advances","first-page":"1664","author":"Xie","year":"2025"},{"key":"10.1016\/j.bbcan.2025.189406_bb0850","series-title":"Current and Future Immunotherapeutic Approaches in Pancreatic Cancer Treatment","first-page":"1756","author":"Farhangnia","year":"2025"},{"key":"10.1016\/j.bbcan.2025.189406_bb0855","series-title":"Immunotherapy Combination Approaches: Mechanisms, Biomarkers and Clinical Observations","first-page":"1474","author":"Butterfield","year":"2025"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189406_bb0860","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202201401","article-title":"Radiation-induced immunogenic cell death for cancer radioimmunotherapy","volume":"7","author":"Liu","year":"2023","journal-title":"Small Methods"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189406_bb0865","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2025.189406_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106663","article-title":"Abscopal effect in radioimmunotherapy","volume":"85","author":"Ashrafizadeh","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbcan.2025.189406_bb0875","series-title":"Local Radiotherapy and Granulocyte-Macrophage Colony-Stimulating Factor to Generate Abscopal Responses in Patients With Metastatic Solid Tumours: A Proof-Of-Principle Trial","first-page":"1474","author":"Golden","year":"2025"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189406_bb0880","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/j.prro.2016.12.004","article-title":"Beware of deintensification of radiation therapy in patients with p16-positive oropharynx cancer and rheumatological diseases","volume":"7","author":"Chera","year":"2017","journal-title":"Pract. Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0885","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s40425-019-0692-z","article-title":"Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade","volume":"7","author":"Liu","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2025.189406_bb0890","series-title":"Combining Radiotherapy And Ipilimumab Induces Clinically Relevant Radiation-Induced Abscopal Effects In Metastatic Melanoma Patients: A Systematic Review","first-page":"2405","author":"Chicas-Sett","year":"2025"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189406_bb0895","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1046028","article-title":"A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab","volume":"4","author":"Chandra","year":"2015","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189406_bb0900","article-title":"Abscopal effect of radiotherapy in the immunotherapy era: systematic review of reported cases","volume":"11","author":"Dagoglu","year":"2019","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189406_bb0905","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/CAD.0000000000000497","article-title":"The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy","volume":"28","author":"Kaidar-Person","year":"2017","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0910","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3171\/2015.6.JNS142763","article-title":"Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?","volume":"125","author":"Colaco","year":"2016","journal-title":"J. Neurosurg."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189406_bb0915","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s11060-017-2470-4","article-title":"Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma","volume":"133","author":"Fang","year":"2017","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.bbcan.2025.189406_bb0920","series-title":"Previous Radiotherapy and the Clinical Activity and Toxicity Of Pembrolizumab in the Treatment of Non-small-cell Lung Cancer: A Secondary Analysis of the KEYNOTE-001 Phase 1 Trial","first-page":"1474","author":"Shaverdian","year":"2025"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189406_bb0925","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijrobp.2017.02.003","article-title":"Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy","volume":"98","author":"Bang","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bbcan.2025.189406_bb0930","series-title":"Clinical Outcomes of Melanoma Brain Metastases Treated With Stereotactic Radiation and Anti-PD-1 Therapy","first-page":"1569","author":"Ahmed","year":"2025"},{"key":"10.1016\/j.bbcan.2025.189406_bb0935","series-title":"Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study","first-page":"1527","author":"Ott","year":"2025"},{"key":"10.1016\/j.bbcan.2025.189406_bb0940","series-title":"Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2--Tumor and Immunological Responses","first-page":"1946","author":"Seung","year":"2025"},{"key":"10.1016\/j.bbcan.2025.189406_bb0945","series-title":"Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors","first-page":"1527","author":"Luke","year":"2025"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189406_bb0950","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11912-020-00986-9","article-title":"The combined use of SBRT and immunotherapy-a literature review","volume":"22","author":"Lubas","year":"2020","journal-title":"Curr. Oncol. Rep."},{"issue":"43","key":"10.1016\/j.bbcan.2025.189406_bb0955","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1038\/onc.2015.5","article-title":"Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience","volume":"34","author":"Gao","year":"2015","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189406_bb0960","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijrobp.2016.04.017","article-title":"Safety and efficacy of radiation therapy in advanced melanoma patients treated with Ipilimumab","volume":"96","author":"Qin","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bbcan.2025.189406_bb0965","series-title":"Timing and Type of Immune Checkpoint Therapy Affect the Early Radiographic Response of Melanoma Brain Metastases to Stereotactic Radiosurgery","first-page":"1097","author":"Qian","year":"2025"},{"key":"10.1016\/j.bbcan.2025.189406_bb0970","series-title":"Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy: A Pooled Analysis of Trials in the US Food and Drug Administration Database","first-page":"2374","author":"Anscher","year":"2025"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189406_bb0975","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cell.2023.12.011","article-title":"Bispecific dendritic-T cell engager potentiates anti-tumor immunity","volume":"187","author":"Shapir Itai","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2025.189406_bb0980","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1200\/EDBK_160766","article-title":"Biomarkers for immunotherapy: current developments and challenges","volume":"35","author":"Spencer","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25001489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25001489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T21:16:04Z","timestamp":1758143764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25001489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":196,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0304419X25001489"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189406","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical aspect of combined immunotherapy and radiotherapy effect on tumor immune microenvironment in hepatobiliary and pancreatic cancers","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189406","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189406"}}